Longevity Biotech

Executive Summary

Longevity Biotech is a clinical-stage biopharmaceutical company developing disease-modifying therapies for neurodegenerative diseases, with an initial focus on Parkinson's Disease. The company leverages two proprietary platforms: Precision Neuroscience, which enables targeted delivery and modulation of neurological pathways, and Hybridtide™, a synthetic peptide technology designed to rebalance the immune system. By combining these platforms, Longevity Biotech aims to create novel therapeutics that address the underlying pathology of neurodegeneration, potentially offering disease-modifying effects rather than symptomatic relief. The company's approach is rooted in the growing understanding of immune dysregulation in Parkinson's and other conditions, positioning it to address a significant unmet need in a market with limited treatment options. Longevity Biotech is a private company based in San Francisco, founded in 2018, and has not disclosed its funding or valuation. Despite this, its focus on a validated target—immune modulation in neurodegeneration—and the use of advanced peptide engineering could provide a competitive edge. The company's lead candidate is likely in early clinical development, and upcoming clinical data will be crucial for validating its platform. If successful, Longevity Biotech could expand into other neurodegenerative indications, such as Alzheimer's disease, and potentially attract partnership interest from larger pharmaceutical companies seeking innovative pipeline assets. The next 12-18 months represent a critical period for the company to demonstrate proof-of-concept and advance toward value inflection points.

Upcoming Catalysts (preview)

• Q3 2026Lead Parkinson's candidate Phase 1/2a interim data readout55% success
• Q2 2027IND filing for second indication (Alzheimer's or related)40% success
• TBDResearch partnership or licensing deal with major pharma30% success